Skip to main content

Table 2 Ability of mesothelin to predict radiological progression depending on cut-off used and radiological reporting method

From: A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

Mesothelin Cut-off 10% 15% 25%
CT reporting method Clinically reported CT MRECIST Clinically reported CT MRECIST Clinically reported CT MRECIST
No. 43 25 43 25 43 25
Sensitivity 95.8 (78.8–99.8) 90.9 (58.7–99.7) 83.3 (62.6–95.3) 72.7 (39.0–93.9) 80.0 (59.3–93.2) 72.7 (39.0–93.9)
Specificity 73.7 (48.8–90.8) 57.1 (28.9–82.3) 84.2 (60.4–96.6) 71.4 (41.9–91.6) 84.2 (60.4–96.6) 71.4 (41.9–91.6)
PPV 82.1 (68.3–90.8) 62.5 (46.9–75.8) 87.0 (69.9–95.0) 66.7 (44.7–83.2) 87.0 (69.9–95.0) 66.7 (44.7–83.2)
NPV 93.3 (66.8–99.0) 88.9 (53.9–98.2) 80 (61.7–90.9) 76.9 (54.6–90.2) 76.2 (58.8–87.8) 76.9 (54.6–90.2)
Accuracy 86.0%   83.7%   0.81%